IL2 and neoplasm: Initial work in the Surgery Branch of the National Cancer Institute found that adoptively transferred IL-2-activated peripheral blood mononuclear cells with the phenotype and functional characteristics of activated NK cells, supported with concomitant administration of IL-2 in high doses, resulted in significant tumor regression in patients selected for normal organ function and good performance status.